Methocarbamol 750 MG Oral Tablet — RxCUI 197944
RxNorm drug concept · Semantic clinical drug
RxCUI 197944
Semantic clinical drug · SCD
● Current RxNorm concept 107 FDA products
378 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI197944
Official nameMethocarbamol 750 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped107
Package NDCs mapped378
Reported Medicaid activity (SDUD)1,310,003 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Methocarbamol: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Methocarbamol is a muscle relaxant that works through your central nervous system — your brain and spinal cord — rather than directly on the muscles themselves. It's thought to red...
- What exactly does methocarbamol do? Will it make my muscles stop hurting?
- You really should not. Methocarbamol already causes drowsiness and slows your central nervous system down. Adding alcohol on top of that significantly increases those effects — we'...
- Be careful, especially when you first start taking it. Methocarbamol can impair your alertness, coordination, and reaction time. Don't drive or operate heavy machinery until you kn...
🕸️ Concept Web — How Methocarbamol 750 MG Oral Tablet Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Methocarbamol 750 MG Oral Tablet
RxCUI 197944 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Methocarbamol
6845IN
-
Methocarbamol
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Robaxin
202955BN
-
Robaxin
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Methocarbamol Oral Tablet
372831SCDF -
Methocarbamol Oral Product
1162231SCDG -
Methocarbamol Pill
1162232SCDG -
Methocarbamol Oral Tablet [Robaxin]
368800SBDF -
Robaxin Oral Product
1185926SBDG -
Robaxin Pill
1185927SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Methocarbamol Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Methocarbamol 750 MG
317422SCDC -
Methocarbamol 750 MG Oral Tablet [Robaxin]
1010654SBD -
Methocarbamol 750 MG [Robaxin]
1010653SBDC
-
Methocarbamol 750 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Methocarbamol 750 MG
SCDC · 317422 -
Methocarbamol Oral Tablet
SCDF · 372831 -
Methocarbamol Oral Product
SCDG · 1162231 -
Methocarbamol Pill
SCDG · 1162232
Brand-Name Concepts
-
Methocarbamol 750 MG Oral Tablet [Robaxin]
SBD · 1010654 -
Methocarbamol 750 MG [Robaxin]
SBDC · 1010653 -
Methocarbamol Oral Tablet [Robaxin]
SBDF · 368800 -
Robaxin Oral Product
SBDG · 1185926 -
Robaxin Pill
SBDG · 1185927 -
Robaxin
BN · 202955
📦 FDA Products & Package NDCs
107 products · 378 package NDCs
378 package NDCs map to RxCUI 197944 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 85534-0022-00 | 30 TABLET in 1 BOTTLE (85534-0022-0) | Methocarbamol | HAWAII REPACK, INC. | 2026-06-25 |
| 85534-0022-01 | 60 TABLET in 1 BOTTLE (85534-0022-1) | Methocarbamol | HAWAII REPACK, INC. | 2026-06-25 |
| 85534-0022-02 | 90 TABLET in 1 BOTTLE (85534-0022-2) | Methocarbamol | HAWAII REPACK, INC. | 2026-06-25 |
| 85534-0022-03 | 120 TABLET in 1 BOTTLE (85534-0022-3) | Methocarbamol | HAWAII REPACK, INC. | 2026-06-25 |
| 85534-0057-00 | 30 TABLET in 1 BOTTLE (85534-0057-0) | Methocarbamol | HAWAII REPACK, INC. | 2026-06-25 |
| 85534-0057-01 | 60 TABLET in 1 BOTTLE (85534-0057-1) | Methocarbamol | HAWAII REPACK, INC. | 2026-06-25 |
| 85534-0057-02 | 90 TABLET in 1 BOTTLE (85534-0057-2) | Methocarbamol | HAWAII REPACK, INC. | 2026-06-25 |
| 85534-0057-03 | 120 TABLET in 1 BOTTLE (85534-0057-3) | Methocarbamol | HAWAII REPACK, INC. | 2026-06-25 |
| 85766-0060-01 | 100 TABLET, FILM COATED in 1 BOTTLE (85766-060-01) | Methocarbamol | Sportpharm LLC | 2025-08-29 |
| 85766-0060-05 | 500 TABLET, FILM COATED in 1 BOTTLE (85766-060-05) | Methocarbamol | Sportpharm LLC | 2025-08-29 |
| 85766-0060-21 | 21 TABLET, FILM COATED in 1 BOTTLE (85766-060-21) | Methocarbamol | Sportpharm LLC | 2026-04-03 |
| 85766-0060-28 | 28 TABLET, FILM COATED in 1 BOTTLE (85766-060-28) | Methocarbamol | Sportpharm LLC | 2025-08-29 |
| 85766-0060-30 | 30 TABLET, FILM COATED in 1 BOTTLE (85766-060-30) | Methocarbamol | Sportpharm LLC | 2025-08-29 |
| 85766-0060-42 | 42 TABLET, FILM COATED in 1 BOTTLE (85766-060-42) | Methocarbamol | Sportpharm LLC | 2025-08-29 |
| 85766-0060-60 | 60 TABLET, FILM COATED in 1 BOTTLE (85766-060-60) | Methocarbamol | Sportpharm LLC | 2025-08-29 |
| 85766-0060-90 | 90 TABLET, FILM COATED in 1 BOTTLE (85766-060-90) | Methocarbamol | Sportpharm LLC | 2025-08-29 |
| 87063-0040-01 | 100 TABLET, FILM COATED in 1 BOTTLE (87063-040-01) | Methocarbamol | Asclemed USA, Inc. | 2025-11-24 |
| 87063-0040-10 | 10 TABLET, FILM COATED in 1 BOTTLE (87063-040-10) | Methocarbamol | Asclemed USA, Inc. | 2025-11-24 |
| 87063-0040-20 | 20 TABLET, FILM COATED in 1 BOTTLE (87063-040-20) | Methocarbamol | Asclemed USA, Inc. | 2025-11-24 |
| 87063-0040-30 | 30 TABLET, FILM COATED in 1 BOTTLE (87063-040-30) | Methocarbamol | Asclemed USA, Inc. | 2025-11-24 |
| 87063-0040-60 | 60 TABLET, FILM COATED in 1 BOTTLE (87063-040-60) | Methocarbamol | Asclemed USA, Inc. | 2025-11-24 |
| 87063-0040-90 | 90 TABLET, FILM COATED in 1 BOTTLE (87063-040-90) | Methocarbamol | Asclemed USA, Inc. | 2025-11-24 |
| 87063-0041-01 | 100 TABLET, FILM COATED in 1 BOTTLE (87063-041-01) | Methocarbamol | Asclemed USA, Inc. | 2025-11-24 |
| 87063-0041-10 | 10 TABLET, FILM COATED in 1 BOTTLE (87063-041-10) | Methocarbamol | Asclemed USA, Inc. | 2025-11-24 |
| 87063-0041-20 | 20 TABLET, FILM COATED in 1 BOTTLE (87063-041-20) | Methocarbamol | Asclemed USA, Inc. | 2025-11-24 |
| 87063-0041-30 | 30 TABLET, FILM COATED in 1 BOTTLE (87063-041-30) | Methocarbamol | Asclemed USA, Inc. | 2025-11-24 |
| 87063-0041-60 | 60 TABLET, FILM COATED in 1 BOTTLE (87063-041-60) | Methocarbamol | Asclemed USA, Inc. | 2025-11-24 |
| 87063-0041-90 | 90 TABLET, FILM COATED in 1 BOTTLE (87063-041-90) | Methocarbamol | Asclemed USA, Inc. | 2025-11-24 |
Observed labelers:
Bryant Ranch Prepack (70) ·
Proficient Rx LP (41) ·
Asclemed USA, Inc. (38) ·
A-S Medication Solutions (25) ·
PD-Rx Pharmaceuticals, Inc. (25) ·
Aphena Pharma Solutions - Tennessee, LLC (24)
· +32 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.